ERBB4 EXPRESSION

CI-VAR-00000915Explore in graph →CIViC 365

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
HER2-Positive Breast Carcinoma2
ERBB4 EXPRESSION	(prognostic)	Prognostic	B	Supports Poor Outcome	3	submitted	EID1961 Preventing HER4 cleavage by a γ-secretase inhibitor and inhibiting HER4 tyrosine kinase activity by neratinib decreased trastuzumab-induced HER4 nuclear translocation and enhanced trastuzumab response… (full text at CIViC) PMID 25153719 · Mohd Nafi et al., 2014 · Open in CIViC	civic
ERBB4 EXPRESSION	Trastuzumab	Predictive	D	Supports Resistance	2	accepted	EID868 siRNA knockdown of HER4 or inhibition with neratinib enhanced trastuzumab response in breast cancer cell lines. PMID 25153719 · Mohd Nafi et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.